Effect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats

다국어 초록 (Multilingual Abstract)

Metformin has been reported to increase the expression of the glucagon-like peptide-1 (GLP-1) receptor in pancreatic beta cells in a peroxisome proliferator-activated receptor (PPAR)-a-dependent manner. We investigated whether a PPARa agonist,fenofibrate, exhibits an additive or synergistic effect on glucose metabolism, independent of its lipid-lowering effect, when added to metformin. Non-obese diabetic Goto-Kakizaki (GK) rats were divided into four groups and treated for 28 days with metformin, fenofibrate, metformin plus fenofibrate or vehicle. The random blood glucose levels, body weights, food intake and serum lipid profiles were not significantly different among the groups. After 4 weeks, metformin, but not fenofibrate, markedly reduced the blood glucose levels during oral glucose tolerance tests, and this effect was attenuated by adding fenofibrate.
Metformin increased the expression of the GLP-1 receptor in pancreatic islets, whereas fenofibrate did not. During the intraperitoneal glucose tolerance tests with the injection of a GLP-1 analog, metformin and/or fenofibrate did not alter the insulin secretory responses. In conclusion, fenofibrate did not confer any beneficial effect on glucose homeostasis but reduced metformin’s glucose-lowering activity in GK rats, thus discouraging the addition of fenofibrate to metformin to improve glycemic control.

참고문헌 (Reference)

1 Olefsky JM, "Treatment of insulin resistance with peroxisome proliferatoractivated receptor gamma agonists" 106 : 467-472, 2000

2 Oh TJ, "The incretin effect in korean subjects with normal glucose tolerance or type 2 diabetes"

3 Kieffer TJ, "The glucagon-like peptides" 20 : 876-913, 1999

4 Drucker DJ, "The biology of incretin hormones" 3 : 153-165, 2006

5 Portha B, "The GK rat beta-cell: a prototype for the diseased human beta-cell in type 2 diabetes?" 297 : 73-85, 2009

6 Cho YM, "Targeting the glucagon receptor family for diabetes and obesity therapy" 135 : 247-278, 2012

7 Duez H, "Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation" 25 : 585-591, 2005

8 Knop FK, "Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?" 56 : 1951-1959, 2007

9 Nauck M, "Reduced incretin effect in type 2 (non-insulin-dependent) diabetes" 29 : 46-52, 1986

10 Pruski M, "Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia" 32 : 1421-1424, 2009

11 Kang ZF, "Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes" 56 : 423-433, 2013

12 Koh EH, "Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation" 52 : 2331-2337, 2003

13 DeFronzo RA, "Pathogenesis of NIDDM. A balanced overview" 15 : 318-368, 1992

14 Ahren B, "Novel combination treatment of type 2 diabetes DPP-4 inhibitionþmetformin" 4 : 383-394, 2008

15 Nieuwdorp M, "Normalization of metabolic syndrome using fenofibrate, metformin or their combination" 9 : 869-878, 2007

16 Clarke BL, "New selective estrogen and androgen receptor modulators" 21 : 374-379, 2009

17 Cho YM, "New aspects of an old drug: metformin as a glucagonlike peptide 1 (GLP-1) enhancer and sensitiser" 54 : 219-222, 2011

18 Maida A, "Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-alpha in mice" 54 : 339-349, 2011

19 Bailey CJ, "Metformin" 334 : 574-579, 1996

20 Nathan DM, "Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes" 32 : 193-203, 2009

21 Cho YM, "K-cells and glucose-dependent insulinotropic polypeptide in health and disease" 84 : 111-150, 2010

22 Meier JJ, "Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?" 59 : 1117-1125, 2010

23 Chia CW, "Incretin-based therapies in type 2 diabetes mellitus" 93 : 3703-3716, 2008

24 Nauck MA, "Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses" 63 : 492-498, 1986

25 Creutzfeldt W, "Gut hormones and diabetes mellitus" 8 : 149-177, 1992

26 Keech A, "Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial" 366 : 1849-1861, 2005

27 Stege H, "Effect of breeding strategy and feeding system on the within-herd variation of lean meat percents in Danish slaughter pigs" 101 : 73-78, 2011

28 Speck M, "Duodenal-jejunal bypass protects GK rats from {beta}-cell loss and aggravation of hyperglycemia and increases enteroendocrine cells coexpressing GIP and GLP-1" 300 : E923-E932, 2011

29 Xu G, "Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes" 56 : 1551-1558, 2007

30 Lynn FC, "Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats" 50 : 1004-1011, 2001

31 Baggio LL, "Biology of incretins: GLP-1 and GIP" 132 : 2131-2157, 2007

32 Zander M, "Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes" 24 : 720-725, 2001

33 Cuthbertson J, "Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagonlike peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus" 60 : 52-56, 2011